1. Home
  2. GKOS vs FRVO Comparison

GKOS vs FRVO Comparison

Compare GKOS & FRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$185.49

Market Cap

10.9B

Sector

Health Care

ML Signal

N/A

FRVO

Fervo Energy Company Class A common stock

N/A

Current Price

$19.87

Market Cap

10.0B

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
GKOS
FRVO
Founded
1998
N/A
Country
United States
United States
Employees
1094
N/A
Industry
Medical/Dental Instruments
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
10.0B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
GKOS
FRVO
Price
$185.49
$19.87
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
$126.92
N/A
AVG Volume (30 Days)
855.1K
2.9M
Earning Date
04-29-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.32
N/A
Revenue Next Year
$27.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$16.89
52 Week High
$189.69
$41.42

Technical Indicators

Market Signals
Indicator
GKOS
FRVO
Relative Strength Index (RSI) 74.68 37.46
Support Level $99.75 $16.89
Resistance Level N/A $27.83
Average True Range (ATR) 7.77 2.73
MACD 1.39 0.09
Stochastic Oscillator 88.29 34.45

Price Performance

Historical Comparison
GKOS
FRVO

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: